• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝细胞癌切除术后肝内复发:最新进展

Intrahepatic recurrence of hepatocellular carcinoma after resection: an update.

作者信息

Tampaki Maria, Papatheodoridis George Vasileios, Cholongitas Evangelos

机构信息

Academic Department of Gastroenterology, Laiko General Hospital, Medical School of National and Kapodistrian University of Athens, 11527, Athens, Greece.

First Department of Internal Medicine, Laiko General Hospital, Medical School of National and Kapodistrian University of Athens, Agiou Thoma 17, 11527, Athens, Greece.

出版信息

Clin J Gastroenterol. 2021 Jun;14(3):699-713. doi: 10.1007/s12328-021-01394-7. Epub 2021 Mar 27.

DOI:10.1007/s12328-021-01394-7
PMID:33774785
Abstract

Hepatocellular carcinoma recurrence occurs in 40-70% of patients after hepatic resection. Despite the high frequency of hepatocellular cancer relapse, there is no established guidance for the management of such cases. The evaluation of prognostic factors that indicate a high risk of recurrence after surgery such as the tumor number and size and the presence of microvascular invasion may guide the therapeutic strategy and point out which patients should be strictly monitored. Additionally, the administration of adjuvant treatment or ab initio liver transplantation in selected patients with high-risk characteristics could have a significant impact on the prevention of relapse and overall survival. Once the recurrence has occurred in the liver remnant, the available therapeutic options include re-resection, salvage liver transplantation and locoregional treatments, although the therapeutic choice is often challenging and should be based on the characteristics of the recurrent tumor, the patient profile and most importantly the timing of relapse. Aggressive combination treatments are often required in challenging cases of early relapse. The results of the above treatment strategies are reviewed and compared to determine the optimal management of patients with recurrent hepatocellular cancer following liver resection.

摘要

肝切除术后,40%-70%的患者会出现肝细胞癌复发。尽管肝细胞癌复发的频率很高,但对于此类病例的管理尚无既定的指导方针。对术后复发风险高的预后因素进行评估,如肿瘤数量、大小以及微血管侵犯情况,可能会指导治疗策略,并指出哪些患者应进行严格监测。此外,对具有高危特征的特定患者进行辅助治疗或一开始就进行肝移植,可能会对预防复发和总体生存产生重大影响。一旦肝残余出现复发,可用的治疗选择包括再次切除、挽救性肝移植和局部区域治疗,尽管治疗选择通常具有挑战性,应基于复发性肿瘤的特征、患者情况,最重要的是复发时间。对于早期复发的具有挑战性的病例,通常需要积极的联合治疗。对上述治疗策略的结果进行回顾和比较,以确定肝切除术后复发性肝细胞癌患者的最佳管理方案。

相似文献

1
Intrahepatic recurrence of hepatocellular carcinoma after resection: an update.肝细胞癌切除术后肝内复发:最新进展
Clin J Gastroenterol. 2021 Jun;14(3):699-713. doi: 10.1007/s12328-021-01394-7. Epub 2021 Mar 27.
2
[Surgical treatment of primary liver cancer:a report of 10 966 cases].[原发性肝癌的外科治疗:10966例报告]
Zhonghua Wai Ke Za Zhi. 2021 Jan 1;59(1):6-17. doi: 10.3760/cma.j.cn112139-20201110-00791.
3
Treatment for intrahepatic recurrence after curative resection of hepatocellular carcinoma: Salvage liver transplantation or re-resection/radiofrequency ablation? A Retrospective Cohort Study.根治性切除术后肝内复发肝细胞癌的治疗:挽救性肝移植或再次切除/射频消融?一项回顾性队列研究。
Int J Surg. 2017 Oct;46:178-185. doi: 10.1016/j.ijsu.2017.09.001. Epub 2017 Sep 7.
4
Salvage liver transplantation or repeat hepatectomy for recurrent hepatocellular carcinoma: An intent-to-treat analysis.挽救性肝移植或再次肝切除术治疗复发性肝细胞癌:意向治疗分析。
Liver Transpl. 2017 Dec;23(12):1553-1563. doi: 10.1002/lt.24952.
5
Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma.肝细胞癌切除术后复发的危险因素、预防及管理
Ann Surg. 2000 Jul;232(1):10-24. doi: 10.1097/00000658-200007000-00003.
6
The clinical behavior of transplantable recurrent hepatocellular carcinoma after curative resection: implications for salvage liver transplantation.根治性切除术后可移植复发性肝细胞癌的临床行为:对挽救性肝移植的意义
Ann Surg Oncol. 2014 Aug;21(8):2717-24. doi: 10.1245/s10434-014-3597-6. Epub 2014 Jun 11.
7
Aggressive management of patients with extrahepatic and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional therapy.通过联合切除和局部区域治疗积极管理肝细胞癌肝外和肝内复发的患者。
J Am Coll Surg. 2002 Sep;195(3):311-8. doi: 10.1016/s1072-7515(02)01226-7.
8
Feasibility of salvage liver transplantation for patients with recurrent hepatocellular carcinoma.复发性肝细胞癌患者挽救性肝移植的可行性
Clin Transplant. 2005 Apr;19(2):175-80. doi: 10.1111/j.1399-0012.2005.00277.x.
9
Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?肝切除术作为肝硬化合并肝细胞癌患者肝移植的过渡手段:一种合理的策略?
Ann Surg. 2003 Oct;238(4):508-18; discussion 518-9. doi: 10.1097/01.sla.0000090449.87109.44.
10
Advantage of early liver transplantation whenever indicated for hepatocellular carcinoma recurrence after primary liver resection.对于原发性肝癌切除术后肝癌复发,只要有指征,早期肝移植的优势。
Biomed J. 2019 Oct;42(5):335-342. doi: 10.1016/j.bj.2019.04.001. Epub 2019 Oct 29.

引用本文的文献

1
Aberrant angiogenic signaling in HCC: therapeutic targeting and drug resistance.肝癌中异常的血管生成信号传导:治疗靶点与耐药性
Front Oncol. 2025 Jun 18;15:1595195. doi: 10.3389/fonc.2025.1595195. eCollection 2025.
2
Intravoxel Incoherent Motion Improves the Accuracy of Preoperative Prediction of Vessels Encapsulating Tumor Clusters in Hepatocellular Carcinoma.体素内不相干运动提高肝细胞癌中包裹肿瘤簇血管术前预测的准确性。
J Hepatocell Carcinoma. 2025 Jun 11;12:1177-1190. doi: 10.2147/JHC.S519223. eCollection 2025.
3
Strategies for neoantigen screening and immunogenicity validation in cancer immunotherapy (Review).

本文引用的文献

1
Analysis of Endoscopy Findings to Identify Early Gastric Cancers with Tumor Budding: A Retrospective Study.内镜检查结果分析:以肿瘤芽殖识别早期胃癌——一项回顾性研究。
J Gastrointest Surg. 2021 Jul;25(7):1706-1715. doi: 10.1007/s11605-020-04862-6. Epub 2020 Nov 9.
2
Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers.免疫检查点抑制剂治疗胃肠道、肝胆和胰腺癌的现状
Therap Adv Gastroenterol. 2020 Aug 21;13:1756284820948773. doi: 10.1177/1756284820948773. eCollection 2020.
3
Serum STIP1, a Novel Indicator for Microvascular Invasion, Predicts Outcomes and Treatment Response in Hepatocellular Carcinoma.
癌症免疫治疗中新抗原筛选及免疫原性验证策略(综述)
Int J Oncol. 2025 Jun;66(6). doi: 10.3892/ijo.2025.5749. Epub 2025 May 9.
4
The safety and efficacy of tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors combined with HAIC/TACE in the treatment of recurrent unresectable hepatocellular carcinoma.酪氨酸激酶抑制剂和程序性细胞死亡蛋白1抑制剂联合肝动脉灌注化疗/经动脉化疗栓塞术治疗复发性不可切除肝细胞癌的安全性和疗效
BMC Cancer. 2025 Apr 25;25(1):779. doi: 10.1186/s12885-025-14185-x.
5
Dual role of pyroptosis in liver diseases: mechanisms, implications, and therapeutic perspectives.细胞焦亡在肝脏疾病中的双重作用:机制、影响及治疗前景
Front Cell Dev Biol. 2025 Jan 23;13:1522206. doi: 10.3389/fcell.2025.1522206. eCollection 2025.
6
Surgical resection of late extrahepatic metastasis of hepatocellular carcinoma 11 years after initial diagnosis: case report and literature review.肝细胞癌初次诊断11年后肝外晚期转移灶的手术切除:病例报告及文献复习
J Surg Case Rep. 2024 Oct 8;2024(10):rjae632. doi: 10.1093/jscr/rjae632. eCollection 2024 Oct.
7
The Enhanced Role of Eosinophils in Radiomics-Based Diagnosis of Microvascular Invasion and Its Association with the Immune Microenvironment in Hepatocellular Carcinoma.嗜酸性粒细胞在基于影像组学的肝细胞癌微血管侵犯诊断中的增强作用及其与免疫微环境的关联
J Hepatocell Carcinoma. 2024 Sep 25;11:1789-1800. doi: 10.2147/JHC.S484027. eCollection 2024.
8
Clinical Nomogram Model for Pre-Operative Prediction of Microvascular Invasion of Hepatocellular Carcinoma before Hepatectomy.临床列线图模型预测肝癌切除术前行微血管侵犯的术前预测。
Medicina (Kaunas). 2024 Aug 28;60(9):1410. doi: 10.3390/medicina60091410.
9
Advancing microvascular invasion diagnosis: a multi-center investigation of novel MRI-based models for precise detection and classification in early-stage small hepatocellular carcinoma (≤ 3 cm).推进微血管侵犯诊断:一项基于新型MRI模型对早期小肝癌(≤3厘米)进行精确检测和分类的多中心研究。
Abdom Radiol (NY). 2025 May;50(5):1986-1999. doi: 10.1007/s00261-024-04463-w. Epub 2024 Sep 28.
10
Exploring potential predictive biomarkers through historical perspectives on the evolution of systemic therapies into the emergence of neoadjuvant therapy for the treatment of hepatocellular carcinoma.通过系统疗法演变的历史视角,探索潜在的预测生物标志物,直至新辅助疗法出现用于治疗肝细胞癌。
Front Oncol. 2024 Jun 27;14:1429919. doi: 10.3389/fonc.2024.1429919. eCollection 2024.
血清STIP1,一种微血管侵犯的新型指标,可预测肝细胞癌的预后和治疗反应。
Front Oncol. 2020 Apr 30;10:511. doi: 10.3389/fonc.2020.00511. eCollection 2020.
4
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
5
IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.IMbrave 050:阿替利珠单抗联合贝伐珠单抗用于根治性切除或消融治疗后高危肝细胞癌的 III 期临床试验。
Future Oncol. 2020 May;16(15):975-989. doi: 10.2217/fon-2020-0162. Epub 2020 Apr 30.
6
Perioperative outcomes comparing laparoscopic with open repeat liver resection for post-hepatectomy recurrent liver cancer: A systematic review and meta-analysis.腹腔镜与开腹再次肝切除治疗肝癌术后复发的围手术期结局比较:系统评价和荟萃分析。
Int J Surg. 2020 Jul;79:17-28. doi: 10.1016/j.ijsu.2020.03.052. Epub 2020 Mar 30.
7
Treatment optimization for recurrent hepatocellular carcinoma: Repeat hepatic resection versus radiofrequency ablation.复发性肝细胞癌的治疗优化:再次肝切除与射频消融术对比
Cancer Med. 2020 May;9(9):2997-3005. doi: 10.1002/cam4.2951. Epub 2020 Feb 28.
8
Optimizing curative management of hepatocellular carcinoma.优化肝细胞癌的治疗管理
Liver Int. 2020 Feb;40 Suppl 1:109-115. doi: 10.1111/liv.14345.
9
Identification of Platform-Independent Diagnostic Biomarker Panel for Hepatocellular Carcinoma Using Large-Scale Transcriptomics Data.利用大规模转录组学数据鉴定肝细胞癌的平台无关诊断生物标志物组
Front Genet. 2020 Jan 10;10:1306. doi: 10.3389/fgene.2019.01306. eCollection 2019.
10
Advantage of early liver transplantation whenever indicated for hepatocellular carcinoma recurrence after primary liver resection.对于原发性肝癌切除术后肝癌复发,只要有指征,早期肝移植的优势。
Biomed J. 2019 Oct;42(5):335-342. doi: 10.1016/j.bj.2019.04.001. Epub 2019 Oct 29.